Latus Bio
About Latus Bio
Latus Bio develops gene therapy candidates utilizing precision delivery through advanced AAV capsid screening to target central nervous system disorders. Their approach aims to enhance treatment efficacy while minimizing toxicity and the need for frequent administrations, addressing the limitations of current CNS therapies.
```xml <problem> Current gene therapies for central nervous system (CNS) disorders often lack sufficient potency and specificity, leading to high dosage requirements, unwanted immune responses, tissue toxicities, and manufacturing scalability challenges. Existing CNS treatments may also necessitate frequent administrations and can produce side effects that outweigh the therapeutic benefits. </problem> <solution> Latus Bio is developing innovative gene therapy candidates for CNS disorders, utilizing precision delivery through advanced AAV capsid screening. Their approach involves screening millions of novel capsid variants to enhance tissue and cell-specific targeting within the CNS, while minimizing off-target interactions. By optimizing AAV capsids, Latus Bio aims to reduce immunogenicity and toxicity risks, improve treatment efficacy, and decrease the need for frequent administrations. The company's one-time gene therapy candidates are designed to fundamentally change how many CNS diseases are treated. </solution> <features> - Massively-parallel, high-throughput AAV capsid screening platform for identifying novel variants with enhanced CNS targeting capabilities. - Capsids designed for direct delivery with conventional clinical techniques. - AAV-EP+ capsid targeting ependyma/neurons for lysosomal storage disorders and secreted protein therapeutics via ICV administration. - AAV-DB capsid targeting deep brain structures for Parkinson’s and Huntington’s Disease via IP administration. - AAV-Ear capsid targeting inner ear/hair cells for genetic hearing loss via ICV administration. - AAV-PN capsid targeting pan-neuronal tissues for Angelman Syndrome, Rett Syndrome, Frontotemporal dementia, and Alzheimer’s Disease via ICV administration. - AAV-CB capsid targeting the cerebellum for spinocerebellar ataxias and Friedreich Ataxia via ICV and IP administration. - AAV-Vasc capsid targeting brain microvasculature for Glut1 deficiency and lysosomal storage disorders via IV administration. </features> <target_audience> The primary target audience includes patients suffering from CNS disorders such as Huntington’s Disease, Parkinson’s Disease, lysosomal storage disorders, genetic hearing loss, and various neurodegenerative diseases, as well as the clinicians treating these conditions. </target_audience> ```
What does Latus Bio do?
Latus Bio develops gene therapy candidates utilizing precision delivery through advanced AAV capsid screening to target central nervous system disorders. Their approach aims to enhance treatment efficacy while minimizing toxicity and the need for frequent administrations, addressing the limitations of current CNS therapies.
Where is Latus Bio located?
Latus Bio is based in Philadelphia, United States.
When was Latus Bio founded?
Latus Bio was founded in 2022.
How much funding has Latus Bio raised?
Latus Bio has raised 54000000.
- Location
- Philadelphia, United States
- Founded
- 2022
- Funding
- 54000000
- Employees
- 26 employees
- Major Investors
- DCVC Bio, 8VC